anti-il-18bp monoclonal antibody gs-0321
Generic: Anti-IL-18BP Monoclonal Antibody GS-0321
anti-il-18bp monoclonal antibody gs-0321: 1 clinical trial tracked.
anti-il-18bp monoclonal antibody gs-0321 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-il-18bp monoclonal antibody gs-0321, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trials (1)
A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies
Primary endpoint: To evaluate the safety profile of COM503 as monotherapy in participants with advanced malignancies.
Interventionalopen200 targetStarted 2025-01Completion 2027-1111 sites · Israel, United StatesCompugen Ltd